{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:12:28Z","timestamp":1779901948092,"version":"3.53.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The aim of this study was to establish whether patients with multiple comorbidities may be at elevated risk of hyperkalaemia (HK), a potentially life-threatening electrolyte imbalance, and the associated adverse clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This was a retrospective, observational cohort study using UK primary and secondary care data. Adult patients with at least one of: resistant hypertension, chronic kidney disease stage 3+, dialysis, heart failure (HF), and diabetes, were eligible for inclusion. According to their diagnoses, patients were grouped into overlapping cohorts that were updated as multimorbidity progressed. Outcomes of interest were incident HK, all-cause mortality (ACM), and major adverse cardiovascular events (MACE). A total of 673\u00a0686 patients met the eligibility criteria, 36.3% of whom developed multimorbidity during the study period. A consistent U-shaped association was observed between serum K+ level and adjusted incidence of ACM and MACE. Hyperkalaemia was progressively more common with increasing Charlson Comorbidity Index (CCI). Relative to a CCI &amp;lt;3, scores of \u22653 to &amp;lt;6, and \u22656 were associated with 2.9- and 6.2-fold increases, respectively, in crude HK (serum K+ \u22655.0\u2009mmol\/L) incidence rate. In all condition-based cohorts except for HF, there was a clear correlation between increasing CCI and the risk of ACM and MACE associated with hypokalaemia and HK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with a higher CCI are at an increased risk of developing HK and appear more prone to adverse clinical outcomes associated with abnormal serum K+ levels, warranting additional routine clinical monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcaa078","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T03:29:52Z","timestamp":1601954992000},"page":"61-69","source":"Crossref","is-referenced-by-count":11,"title":["Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burden"],"prefix":"10.1093","volume":"8","author":[{"given":"Eskinder","family":"Tafesse","sequence":"first","affiliation":[{"name":"Global Health Economics, AstraZeneca, 101 Orchard Ridge Drive, Gaithersburg, MD, USA, 20878"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurst","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd, Rhymney House, Unit A Copse Walk, Cardiff Gate Business Park, Cardiff, UK, CF23 8RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sugrue","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd, Rhymney House, Unit A Copse Walk, Cardiff Gate Business Park, Cardiff, UK, CF23 8RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Hoskin","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd, Rhymney House, Unit A Copse Walk, Cardiff Gate Business Park, Cardiff, UK, CF23 8RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Badora","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd, Rhymney House, Unit A Copse Walk, Cardiff Gate Business Park, Cardiff, UK, CF23 8RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"Global Health Economics, AstraZeneca, 101 Orchard Ridge Drive, Gaithersburg, MD, USA, 20878"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"James","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, AstraZeneca, Academy House, 136 Hills Road, Cambridge, UK, CB2 8PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd, Rhymney House, Unit A Copse Walk, Cardiff Gate Business Park, Cardiff, UK, CF23 8RB"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"2022030711225936600_qcaa078-B1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2012.5265","article-title":"Designing health care for the most common chronic condition\u2013multimorbidity","volume":"307","author":"Tinetti","year":"2012","journal-title":"JAMA"},{"key":"2022030711225936600_qcaa078-B2","doi-asserted-by":"crossref","DOI":"10.1177\/2235042X19870934","article-title":"Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies","volume":"9","author":"Nguyen","year":"2019","journal-title":"J Comorb"},{"key":"2022030711225936600_qcaa078-B3","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.3399\/bjgp18X695465","article-title":"The epidemiology of multimorbidity in primary care: a retrospective cohort study","volume":"68","author":"Cassell","year":"2018","journal-title":"Br J Gen Pract"},{"key":"2022030711225936600_qcaa078-B4","author":"World Health Organization","year":"2018"},{"key":"2022030711225936600_qcaa078-B5","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","article-title":"The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes","volume":"114","author":"Dzau","year":"2006","journal-title":"Circulation"},{"key":"2022030711225936600_qcaa078-B6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"2022030711225936600_qcaa078-B7","author":"World Health Organization","year":"2016"},{"key":"2022030711225936600_qcaa078-B8","first-page":"487","article-title":"Potassium disorders: hypokalemia and hyperkalemia","volume":"92","author":"Viera","year":"2015","journal-title":"Am Fam Physician"},{"key":"2022030711225936600_qcaa078-B9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2022030711225936600_qcaa078-B10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5414\/CNP62465","article-title":"Hyperkalemia-induced ECG abnormalities in patients with reduced renal function","volume":"62","author":"Esposito","year":"2004","journal-title":"Clin Nephrol"},{"key":"2022030711225936600_qcaa078-B11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum potassium, end-stage renal disease and mortality in chronic kidney disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"2022030711225936600_qcaa078-B12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ehf2.12402","article-title":"Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK","volume":"6","author":"Linde","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2022030711225936600_qcaa078-B13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12882-018-1007-1","article-title":"Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink","volume":"19","author":"Furuland","year":"2018","journal-title":"BMC Nephrol"},{"key":"2022030711225936600_qcaa078-B14","first-page":"iii2","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association","volume":"34(Suppl 3","author":"Hunter","year":"2019","journal-title":"Eur Renal Assoc"},{"key":"2022030711225936600_qcaa078-B15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","article-title":"Drug-induced hyperkalemia","volume":"37","author":"Ben Salem","year":"2014","journal-title":"Drug Saf"},{"key":"2022030711225936600_qcaa078-B16","author":"American Heart Association"},{"key":"2022030711225936600_qcaa078-B17","author":"Medicines and Healthcare Products Regulatory Agency. CPRD linked data","year":"2019"},{"key":"2022030711225936600_qcaa078-B18","author":"Medicines and Healthcare Products Regulatory Agency. Primary care data for public health research"},{"key":"2022030711225936600_qcaa078-B19","author":"Charlson Comorbidity Index (CCI)"},{"key":"2022030711225936600_qcaa078-B20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022030711225936600_qcaa078-B21","author":"R Core Team","year":"2016"},{"key":"2022030711225936600_qcaa078-B22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/CLEP.S218697","article-title":"Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time","volume":"11","author":"Pylv\u00e4l\u00e4inen","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2022030711225936600_qcaa078-B23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2022030711225936600_qcaa078-B24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000448341","article-title":"Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study","volume":"44","author":"Yusuf","year":"2016","journal-title":"Am J Nephrol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaa078\/34415212\/qcaa078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/8\/1\/61\/42751778\/qcaa078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/8\/1\/61\/42751778\/qcaa078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T11:31:50Z","timestamp":1646652710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/8\/1\/61\/5932443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,20]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa078","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2020,10,20]]}}}